Applying the 2019 EULAR/ACR lupus criteria to patients from an established cohort: A Latin American perspective

Guillermo J. Pons-Estel, Manuel Francisco Ugarte-Gil, Guillermina B. Harvey, Daniel Wojdyla, Rosana Quintana, Verónica Saurit, Enrique R. Soriano, Eloisa Bonfa, Loreto Massardo, Mario Cardiel, Luis M. Vila, Russell Griffin, Bernardo A. Pons-Estel, Graciela S. Alarcón

Resultado de la investigación: Contribución a una revistaArtículorevisión exhaustiva

16 Citas (Scopus)

Resumen

To evaluate the performance of the 2019 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) systemic lupus erythematosus (SLE) criteria in terms of earlier patients' classification in comparison to the 1982/1997 ACR or the 2012 Systemic Lupus International Collaborating Clinics (SLICC) criteria. Materials and methods Patients from a Latin America, multiethnic, multicentre cohort, where SLE was defined using the physicians' diagnosis, were included. To calculate the sensitivity of the 2019 EULAR/ACR criteria, the 1982/1997 ACR criteria were considered the gold standard. Additionally, comparison of the 1982/1997 ACR criteria and the 2012 SLICC criteria with the 2019 EULAR/ACR criteria was performed. Results The sensitivity of the 2019 EULAR/ACR criteria when compared with the 1982/1997 ACR criteria as the gold standard was 91.3%. This new set of criteria allowed an earlier SLE patient classification in 7.4% (mean 0.67 years) and 0.6% (mean 1.47 years) than the 1982/1997 ACR and the 2012 SLICC criteria, respectively. Patients accruing the 2019 EULAR/ACR earlier than the 1982/1997 ACR criteria were more likely to have high anti-dsDNA titres; those accruing them later were less likely to have mucocutaneous and joint manifestations; this was not observed when comparing them with the 2012 SLICC criteria. Conclusions The 2019 EULAR/ACR criteria classified earlier only a small proportion of Latin America patients than with the two other criteria sets in real-life clinical practice scenarios. Further studies in different patient populations are needed before these new criteria are adopted worldwide.

Idioma originalInglés
Número de artículoe001097
PublicaciónRMD Open
Volumen6
N.º1
DOI
EstadoPublicada - 20 ene. 2020

Nota bibliográfica

Publisher Copyright:
© © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Huella

Profundice en los temas de investigación de 'Applying the 2019 EULAR/ACR lupus criteria to patients from an established cohort: A Latin American perspective'. En conjunto forman una huella única.

Citar esto